On Invalid Date, Eli Lilly & Co (NYSE: LLY) reported Q4 2023 earnings per share (EPS) of $2.43, up 13.02% year over year. Total Eli Lilly & Co earnings for the quarter were $2.19 billion. In the same quarter last year, Eli Lilly & Co's earnings per share (EPS) was $2.15.
As of Q2 2024, Eli Lilly & Co's earnings has grown -16.02% year over year. This is 15.97 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of -0.05%. Eli Lilly & Co's earnings in the past year totalled $5.24 billion.
What is LLY's earnings date?
Eli Lilly & Co's earnings date is Invalid Date. Add LLY to your watchlist to be reminded of LLY's next earnings announcement.
What was LLY's revenue last quarter?
On Invalid Date, Eli Lilly & Co (NYSE: LLY) reported Q4 2023 revenue of $9.35 billion up 28.1% year over year. In the same quarter last year, Eli Lilly & Co's revenue was $7.30 billion.
What was LLY's revenue growth in the past year?
As of Q2 2024, Eli Lilly & Co's revenue has grown 19.56% year over year. This is 14.87 percentage points higher than the US Drug Manufacturers - General industry revenue growth rate of 4.69%. Eli Lilly & Co's revenue in the past year totalled $34.12 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.